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Abstract
High risk HPV (hrHPV) infection is a necessary cause of cervical cancer but the host genetic determinants of infection are
poorly understood. We enrolled 267 women who presented to our cervical cancer screening program in Abuja, Nigeria
between April 2012 and August 2012. We collected information on demographic characteristics, risk factors of cervical
cancer and obtained samples of blood and cervical exfoliated cells from all participants. We used Roche Linear Array HPV
Genotyping TestH to characterize the prevalent HPV according to manufacturer’s instruction; Sequenom Mass Array to test
21 SNPs in genes/regions previously associated with hrHPV and regression models to examine independent factors
associated with HPV infection. We considered a p,0.05 as significant because this is a replication study. There were 65
women with and 202 women without hrHPV infection. Under the allelic model, we found significant association between
two SNPs, rs2305809 on RPS19 and rs2342700 on TYMS, and prevalent hrHPV infection. Multivariate analysis of hrHPV risk
adjusted for age, body mass index, smoking, age of menarche, age at sexual debut, lifetime total number of sexual partners
and the total number of pregnancies as covariates, yielded a p-value of 0.071 and 0.010 for rs2305809 and rs2342700,
respectively. Our findings in this unique population suggest that a number of genetic risk variants for hrHPV are shared with
other population groups. Definitive studies with larger sample sizes and using genome wide approaches are needed to
understand the genetic architecture of hrHPV risk in multiple populations.
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Introduction
With 75,000 new cases and 50,000 deaths in 2008, cervical
cancer is the commonest cancer in men and women combined and
among women in Sub-Saharan Africa [1]. Globally, it is the
seventh most common cancer among men and women combined,
and the third most common cancer in women globally [2,3]. The
disease is not uncommon in developed countries either. For
example in the United States, approximately 11,000 new cases of
cervical cancer were diagnosed in 2007 [4] compared with 14,500
in Nigeria which has half the population of the US [4]. Therefore
while the burden of cervical cancer falls disproportionately on low
resource countries; it remains a significant public health problem
even in developed countries.
Persistent high risk HPV infection (hrHPV) is recognized as a
necessary but not sufficient cause for Cervical Intraepithelial
Neoplasm (CIN) grades 2/3 and cervical cancer (CIN2+) [5].
Several observation suggests that heritable factors have a role in
HPV infection [6]. A review of 15 studies on heritability of cervical
cancer risk suggested that having a first degree relative with
cervical cancer increases an individual’s risk by one to two fold [7].
Magnusson et al in a study of Swedish cancer registry data
demonstrated an association between heritability and cervical
cancer [8] while comparisons of cervical cancer incidence among
mono- and dizygotic twins support a genetic contribution to
development of cervical cancer in situ [9]. Another review of a
potential role for genetic factors in cervical cancer in situ estimated
the heritability to be between 11 and 15% [10,11,12]. Similarly
the heritability of cervical carcinoma was estimated to be ,27%
(95%CI = 26%–29%) reflecting the multifactorial nature of
cervical carcinogenesis as well as the impact of environmental
factors on its development [11,12].
Improved understanding of the etiology, development of new
methods of risk stratification including identification of genetic
markers of hrHPV infection and CIN2+ will benefit citizens in
developed and developing countries. In previous studies, SNPs in
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305 genes based on a priori hypotheses of association with HPV
infection and cervical cancer were evaluated and several loci of
interest identified [13,14]. Of these, genes/regions in the immune
genes 29,59 oligoadenylate synthetase gene 3 (OAS3), sulfatase 1
(SULF1), epidermal dysplasia verruciformis (EV)-associated EV-
ER1 and EVER2 genes, transmembrane channel-like 6 and 8
(TMC6, TMC8), peroxiredoxin 3 (PRDX3), ribosomal protein S19
(RPS19), interleukin 2 receptora (IL2RA), telomere maintenance 2
(TELO2), thymidylate synthetase (TYMS) and complement com-
ponent 1, r subcomponent-like (C1RL) were associated with
components of the cervical carcinogenesis pathway [14].
In this study, we sought to replicate the association between
these genes/regions and risk of prevalent hrHPV infection in an
African population.
Methods
Study participants and ethics
The study was approved by the National Health Research
Ethics Committee of Nigeria.
Women were recruited from 2 cervical cancer screening clinics
within the National Hospital, Abuja and University of Abuja
Teaching Hospital, Abuja, Nigeria during the period April 2012 to
August 2012. To be eligible to enroll in the study, the participants
had to be above the age of 18 and provide written informed
consent for the study. We excluded women who had had a total
hysterectomy, were pregnant or could not provide an informed
consent. A total number of 278 women were screened, of which
267 (96%) had complete phenotype data and were successfully
genotyped (as described below). These 267 women comprised 65
women with prevalent hrHPV (cases) and 202 controls.
Using interviewer administered questionnaires, participants
provided information on demographics, socio-economic status,
physical activity, smoking, alcohol use, sexual and reproductive
history. A gynecologic examination was carried out on each
participant. During the gynecologic examination, exfoliated
cervical cells were collected from the cervical os. A cervical brush
was inserted into the cervical os and rotated 3 full turns to collect
exfoliated cells from the cervical os. The head of the brush was
subsequently snapped off and placed at the bottom of a specimen
transport tube containing 95% ethanol. In addition to the
gynecologic specimens collected, blood samples were also collected
from the antecubital veins. All samples were transported to the
IHVN laboratory. The exfoliated cervical cells were stored at
280uC until the time of analysis. Buffy coat was separated from
the whole blood samples and stored till the time of analysis. Data
were collected and managed using REDCap electronic data
capture tools hosted at the Institute of Human Virology, Nigeria
[15,16].
Laboratory methods
Frozen buffy coat was thawed quickly in a 37uC water bath with
mild agitation and stored on ice before beginning the DNA
extraction procedure. Approximately 500ul leukocyte-containing
fraction was used in the extraction of germline DNA using Gentra
Puregene DNA kitH according to manufacturer’s instructions.
Some 250 ml of DNA hydration solution was added and incubated
at 65uC for 1 hour to dissolve the DNA which was then stored.
DNA samples were shipped to the Center for Research on
Genomics and Global Health, National Human Genome
Research Institute, National Institutes of Health, Bethesda for
analysis.
DNA samples were quantified using Quant-iTTM PicoGreenH
dsDNA reagents and kit (Invitrogen- Life Technologies, Grand
Island, NY). After quantification, DNA samples were normalized
to 100 gg/mL. To obtain the quantity of DNA required for the
genotyping protocol, samples were further diluted to 3.3 gg/mL
and 2 ml of the later concentration were used to stamp the 384-
well plates used for genotyping.
The SNPs were genotyped at the National Human Genome
Institute (NHGRI, NIH) using iPLEX Gold assay on the
MassArray platform (Sequenom, San Diego, CA) as previously
described [17]. This platform allows multiplexing SNPs for
moderate to high throughput genotyping and uses single-base
primer extension chemistry with MALDI-TOF MS technology for
detection. Briefly, the PCR and extension primers were designed
using MassArray designer Software, the Sequence information
were imported from public databases for all SNPs included in this
study. The designed PCR and extension primers were then
ordered (IDT-DNA, Coralville, IA).
The PCR reaction was at a final volume of 5 ml per well. The
PCR mixture contained 106 PCR buffer, MgCl2 (25 mM),
dNTPs (25 mM each), Primer mix (500 nM each) and HotStar
Taq (5 U/uL). PCR conditions were as follows: denaturation at
Figure 1. Distribution of hrHPV types among Nigerian women.
doi:10.1371/journal.pone.0066930.g001
Table 1. Characteristics of the study participants.
Characteristic Cases Controls P value*
N 65 202
Age (years), Mean 6 SD 34.36
(7.4)
37.6
(7.7)
0.002
BMI (kg/m2), Mean 6 SD 25.06
(5.1)
27.6
(6.0)
0.0008
Smoking (%) 1.5 3.5 0.425
Age at menarche (years)# 15
(14, 16)
15
(13, 15.5)
0.015
Age at sexual debut (years) # 19
(16, 23)
19
(18, 22)
0.606
Number of pregnancies had# 2
(0, 3.5)
2
(1, 3)
0.595
Total number of sexual
partners (lifetime) #
3
(1,4)
3
(1,4)
0.723
#Median (25th percentile, 75th percentile).
*P value for Student t (age, BMI), chi-square (smoking) or Wilcoxon rank sum (all
other variables) tests.
doi:10.1371/journal.pone.0066930.t001
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95uC for 15 minutes, followed by 45 cycles of 20 seconds at 95uC,
30 seconds at 56uC, 1 minute at 72uC, and a final extension of
3 minutes at 72uC. Then all wells are treated with Shrimp Alkaline
Phosphatase (SAP) to remove un-incorporated dNTPs. After
optimization of the extension primers and adjustment of the input
concentrations, the iPlex extension primer reaction was carried out
to identify genotypes following the manufacturer’s recommenda-
tions. Each sample was run in duplicate. A total of 29 SNPs split
into 2 plexes of 13 SNPS and 16 SNPs respectively, were
genotyped. The Typer 4.0 software (Sequenom) was used to
process and analyze genotype calls.
The genotyping assay succeeded for 26 SNPs of the 29 SNPs
tried. Four samples were excluded for having failed genotyping at
4 or more loci (i.e. sample success rate ,80%). Applying further
quality control filters resulted in dropping one SNP that had
,90% success rate, 1 SNP for being inconsistent with Hardy-
Weinberg equilibrium (HWE) expectations (P (HWE) ,0.05), two
SNPs for being monomorphic or invariant and one SNP with a
Minor Allele Frequency (MAF) ,0.05. The final association
dataset comprised 21 SNPs on 267 subjects. The overall
genotyping rate for this dataset was 98.7%. Concordance of
duplicate genotypes was 99.9%.
Table 2. SNPs tested for association with hrHPV infection among Nigerian women.
Rank SNP Gene [ref] Chromosome
Minor
Allele
MAF
Cases
MAF
Controls Allelic Model Logistic Model
OR and
95% CI
P-
value
OR and
95% CI
P-
value
1 rs2305809 RPS19 [18] 19q13.2 T 0.0385 0.0990 0.3640
(0.1405, 0.9427)
0.0306 0.3936
(0.1428, 1.0850)
0.0714
2 rs2342700 TYMS [18] 18p11.32 C 0.3154 0.4183 0.6406
(0.4211, 0.9744)
0.0366 0.5328
(0.3293, 0.8619)
0.0103
3 rs4786772 TELO2 [18] 16p13.3 G 0.3387 0.4313 0.6753
(0.4411, 1.0340)
0.0699 0.7410
(0.4666, 1.1770)
0.2040
4 rs6926723 GTF2H4 [17] 6p21.3 A 0.0806 0.1218 0.6323
(0.3098, 1.2910)
0.2047 0.5523
(0.2415, 1.2630)
0.1596
5 rs5757133 DMC1 [17] 17q25.1 T 0.1077 0.0767 1.4520
(0.7471, 2.8230)
0.2690 1.6050
(0.7674, 3.3570)
0.2089
6 rs11177074 IFNG [17] 12q14 C 0.2231 0.1856 1.2600
(0.7770, 2.0420)
0.3485 1.0830
(0.6119, 1.9170)
0.7843
7 rs4737999 SULF1 [17] 8q13.3 A 0.0937 0.0693 1.3890
(0.6846, 2.8190)
0.3608 1.1170
(0.5129, 2.4320)
0.7809
8 rs17132382 POLN [17] 4p16.2 T 0.4462 0.4901 0.8381
(0.5635, 1.2470)
0.3830 0.7656
(0.4946, 1.1850)
0.2306
9 rs12307655 OAS1 [17] 12q24.2 C 0.3846 0.4254 0.8443
(0.5632, 1.2660)
0.4124 0.8858
(0.5534, 1.4180)
0.6136
10 rs7251 IRF3 [18] 19q13.3-q13.4 C 0.2891 0.2562 1.1800
(0.7579, 1.8380)
0.4629 1.1300
(0.6901, 1.8520)
0.6264
11 rs10108002 SULF1 [17] 8q13.3 T 0.1231 0.1015 1.2430
(0.6719, 2.2980)
0.4880 1.0350
(0.5015, 2.1370)
0.9253
12 rs2239359 FANCA [18] 16q24.3 C 0.2422 0.2662 0.8811
(0.5557, 1.3970)
0.5903 0.8230
(0.4994, 1.3560)
0.4446
13 rs16970849 TMC8 [17] 17q25 A 0.2656 0.2438 1.1220
(0.7129, 1.7660)
0.6187 1.0900
(0.6514, 1.8250)
0.7423
14 rs2290907 TNRC6C [17] 17 C 0.4000 0.4229 0.9098
(0.6081, 1.3610)
0.6455 1.0410
(0.6518, 1.6640)
0.8651
15 rs7190823 FANCA [18] 16q24.3 T 0.2462 0.2277 1.1070
(0.6978, 1.7570)
0.6651 1.1040
(0.6533, 1.8650)
0.7121
16 rs2894054 GTF2H4 [17] 6p21.3 A 0.1769 0.1683 1.0620
(0.6312, 1.7870)
0.8204 1.2110
(0.6733, 2.1780)
0.5228
17 rs12302655 OAS3 [17] 12q24.2 A 0.4692 0.4802 0.9570
(0.6441, 1.4220)
0.8276 1.1570
(0.7320, 1.8280)
Q
18 rs3784621 DUT [17] 15q15-q21.1 T 0.3769 0.3663 1.0460
(0.6955, 1.5740)
0.8278 0.9314
(0.6013, 1.4430)
0.7502
19 rs2476491 IL2RA [18] 10p15-p14 T 0.1102 0.1173 0.9313
(0.4846, 1.7900)
0.8308 1.0070
(0.5138, 1.9730)
0.9840
20 rs718802 OAS2 [17] 12q24.2 C 0.4683 0.4722 0.9842
(0.6586, 1.4710)
0.9380 0.9579
(0.6069, 1.5120)
0.8535
21 rs7195066 FANCA [18] 16q24.3 C 0.3047 0.3021 1.0120
(0.6554, 1.5640)
0.9557 0.8788
(0.5415, 1.4260)
0.6009
CI = Confidence Interval.
doi:10.1371/journal.pone.0066930.t002
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HPV DNA extraction and genotyping were done from
ectocervical cell samples. The HPV DNA genotyping was done
using LINEAR ARRAY HPV Genotyping Test (HPV LA; Roche
Diagnostics, IN) based on the principle of DNA amplification by
Polymerase Chain Reaction (PCR) and nucleic acid hybridization.
This genotyping test qualitatively detects 37 high- and low-risk
human papillomavirus genotypes (13-high risk HPV types- 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68; and 24 low-risk HPV
types 26, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71,
72, 73, 81, 82, 83, 84, IS39, CP6108) following a four stage
process of sample preparation, DNA amplification through PCR
protocol using biotinylated PGMY 09/11 L1 region consensus
primer, hybridization and immobilization of the amplified product
to HPV genotype-related oligonucleotide probes and the capturing
of detectable colored bands of amplified products on a LINEAR
ARRAY HPV genotyping strip.
The ectocervical samples were into two separate Sarstead tubes.
These were centrifuged at 20,000 rpm for 5 minutes to pellet the
cells. The liquid supernatant was removed and the tubes were
allowed to dry at either 50uC in hot oven or overnight at room
temperature in a level 2 safety working cabinet. The dry cell pellets
were underwent enzymatic cell lysis, denaturing by detergent and
elution at high temperatures. The process isolates the human b-
globin gene. The digestion solution is a mixture of 1x Proteinase
K-Laureth Digestion Buffer containing proteinase K/ml, 2% (vol/
vol) Laureth-12 (50 mM), Tris-HCl (pH 8.5) –1 mM EDTA. A
total of 100 mL of the buffer is added to the tubes containing the
dry sample. The tubes were vortexed vigorously and digested at
65uC with shaking at 1050 rpm for 30 minutes. The vortexing and
digestion condition were repeated once followed by inactivation of
the proteinase K lysing enzyme at 95uC for 15 minutes without
shaking. Gloves were changed intermittently to avoid cross
contamination of sample.
Amplification involved a pool of biotinylated primers in a PCR
mastermix that specifically binds to designated sequences of
nucleotide on the L1 region of the HPV genome. The primer pool
which includes additional primer pair for the human b-globin
allows for the amplification of HPV DNA from 37 high and low-
risk human papillomavirus genotypes and b-globin gene. The
amplification of the b-globin gene serves as an internal control for
cervical cell adequacy, DNA extraction and amplification. A total
of 5 mL of the digested DNA sample was added to 96 well PCR
plate with 50 mL of HPV LINEAR ARRAY mastermix solution.
The amplification was run on the conventional principle of
polymerase activation and denaturing of the viral and human
genomic DNA to expose the template DNA for primer to anneal
to the target DNA sequence upon cooling. The polymerase
extends the primers to produce complementary bases of double
stranded HPV or the human b-globin DNA molecules. As the
cycle continues, the target nucleic acid sequence on HPV or the
human b-globin DNA is amplified. The target nucleic acid
amplification in the Linear array genotyping test was enhanced by
the inclusion of AmpErase enzyme and deoxyuridine triphosphate
(dUTP) in the master mix. The addition of denaturing solution
and high temperature above 55uC during the amplification
inactivates the AmpErase and prevents the degradation of the
target amplicon by the enzyme. The amplification was performed
on Applied Biosystems Gold-plated 96-well GeneAmp PCR
System 9700 as specified by the manufacturer. Appropriate
volumes for controls of contamination and assay sensitivity were
added in the 96-well assay.
The hybridization assay was performed on Tecan ProfiBlot-48
robots (Tecan, Austria) using the Roche HPV Linear Array
detection solutions. The samples were the denatured HPV or the
human b-globin amplification products. Each Linear Array HPV
genotyping strip coated with HPV, human b-globin and cross-
reactive oligonucleotide probes (for HPV genotype 33, 35, 52 and
58) was placed on wells of the hybridization tray. Denatured biotin
labelled amplicons and hybridization buffer were also transferred
to the wells. As the reaction progresses with continuous but slow
agitation rate, the amplicons sequence hybridizes and matches
complementary oligonucleotide probes on the strip.
The strips were automatically washed to remove any unbound
material followed by binding of Streptavidin-Horseradish Perox-
idase conjugate (SA-HRP) to the strips. A second wash removes
unbound SA-HRP. The SA-HRPcatalyzes 3,39,5,59 -tetramethyl-
benzidine (TMB) in the presence of Hydrogen peroxide to form
detectable blue colour complex that emerges at the point of
hybridization. Each HPV type was detected visually by a type-
specific probe masked on the genotyping strip except for HPV 52.
The detection of the latter depends on a probe that cross
hybridizes with HPV 33, 35, 52 and 58. HPV 52 can only be
inferred if the cross-reactive probe is hybridized in the absence of
any of the HPV 33, 35 and 58 type-specific probes. The HPV
genotypes strip result was interpreted by two independent readers
across a reference template supplied by the manufacturer along
with the detection kit. The consensus result was compared by a
third reviewer with custom computer application result reader.
Statistical analysis
Association analysis was done using PLINK version 1.07 [18].
Two models were considered. In the first model, association was
done under an allelic model. This model is a case-control analysis
that compares allele frequencies between cases and controls with
no adjustment for covariates. The second model was a logistic
model adjusting for age, body mass index (BMI), smoking, age at
menarche, age at sexual debut, lifetime total number of sexual
partners and total number of pregnancies had, assuming an
additive genetic model. Given the prior information about the role
of the tested variants in hrHPV, we considered this study a
replication study, therefore, nominal p-values ,0.05 were
considered significant.
Results
There were 267 women, 65 with hrHPV and 202 controls
enrolled in this study. The characteristics of the participants are
shown in Table 1. Participants with hrHPV were slightly younger
and had lower BMI than controls (Table 1). Cigarette smoking was
uncommon in this population, with only three percent of
participants reporting smoking. The distribution of the hrHPV
types is shown in Figure 1. The most common hrHPV types were
HPV35 found in 15 women (23.1%), HPV59, HPV58 and
HPV56 each found in 10 women (15.4%), HPV45 found in 9
women (13.9%) and HPV68 found in 8 women (12.3%). The
others were HPV18 in 7 women (10.8%), HPV39 in 6 (9.2%),
HPV16 in 6 (9.2%), HPV33 in 5 (7.7%), HPV31 in 4 (6.2%), and
HPV52 and HPV51, each in 3 women (4.6%). Forty-four (67.7%)
of the 65 hrHPV positive subjects had a single hrHPV type. The
other 21 (32.3%) had two or more hrHPV types, comprising 15
subjects with two types, four with three types and one subject each
with 4 types and 6 types, respectively.
Two SNPs, rs2305809 (RPS19) and rs2342700 (TYMS), were
significant under the allelic model (Table 2). Adjusting for age,
BMI and smoking made the association stronger for rs2342700,
with the p-value going from 0.037 to 8.9161023 (data not shown).
Further adjustment of the model for the age of menarche, age at
sexual debut, lifetime total number of sexual partners and the total
SNPs and HPV Infection in Nigerian Women
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number of pregnancies yielded a p value of 0.071 and 0.010 for
rs2305809 and rs2342700, respectively (Table 2). Notably, both of
these SNPs are highly differentiated between African ancestry and
European ancestry populations (with frequencies rs2305809 (T)
0.045 in YRI versus 0.505 in CEU, rs2342700(C) 0.258 YRI versus
0.642 CEU). This suggests that these two SNPS are significantly
associated with hrHPV across multiple ethnic groups despite allele
frequency differences. The association findings for all 21 SNPs
tested are presented in Table 2.
Discussion
In this study of genetic risk of prevalent hrHPV infections in
Nigerian women, we found significant associations with SNPs on
ribosomal protein gene S19 (RPS19) and Thymidylate Synthase
gene (TYMS), in the allelic model. This risk remained significant,
after adjusting for age, body mass index, smoking, age at
menarche, age at sexual debut, lifetime total number of sexual
partners and the total number of pregnancies.
RPS19 is a ribosomal protein expressed by hematopoietic and
non-hematopoietic tissues. Mutations of this ribosomal gene have
been associated with Diamond-Blackfan anemia. Individuals with
this form of anemia have been shown to have increased risk of
malignancies including osteosarcoma, breast, liver, gastric cancers
and hematological malignancies (acute myeloid and lymphoblastic
leukemia, lymphoma, myelodysplasia) [19,20,21,22]. In one
previous study, RPS19 has also been shown to be associated with
the risk of cervical cancer and persistence of HPV [14]. Our results
confirm this previous finding that a SNP on RPS19 is associated
with risk of hrHPV infection. The mechanism of this association is
not yet known and requires further study.
TYMS, the protein product of the TYMS gene, catalyzes the
synthesis of thymidylate, or deoxythymidine monophosphate
(dTMP), from deoxyuridine monophosphate (dUMP) with 5,10-
methylenetetrahydrofolate as the methyl donor [23]. dTMP is
subsequently phosphorylated to thymidine triphosphate, which is
used for DNA synthesis and repair. Enhanced TYMS activity has
been shown to be associated with reduced risk for hepatocellular
cancer [23]. We found an association between a SNP in this gene
and risk of hrHPV infection. This finding confirms the report by
Safaeian et al and together with the RPS19 finding raises
innovative questions about biological pathways that may be
associated with hrHPV and possibly other viral infections [13,14].
This is the first study investigating genetic determinants of
hrHPV infections in Africans and while we confirm 2 of the
previously reported genetic risk factors, we did not find any
association with the other SNPs that had been previously reported.
Our results supports a hitherto unsuspected role for ribosomal and
mitochondrial processes in hrHPV infection. It is possible that
such processes play a role in other viral oncogenes or are uniquely
related to hrHPV infection.
Our study has several limitations. We evaluated association
between these SNPs and prevalent hrHPV infection which has a
weaker association with cervical cancer and precancer. However,
we continue to follow up these participants and will be able to
evaluate whether these associations change with persistence of
hrHPV infection in future. We were not able to evaluate the
association of RPS19 and TYMS with specific types of hrHPV
because of small sample size. Since our study is continuing, we
should be able to do this in future. We focused on hrHPV infection
in this paper and did not consider cervical cancer or precancer.
While these genetic factors may be associated with hrHPV
infection, they may not be or have very weak association with
cervical cancer. Nevertheless, given the strong association between
hrHPV infection and cervical carcinogenesis, they may contribute
to understanding the biological mechanisms and risk stratification.
In conclusion, we present novel findings of the genetic risk
factors for hrHPV infection among African women. Although
several risk factors for hrHPV infection have been established,
there has been little work on the genetic risks. Our findings
support the use of hypothesis free methods to evaluate these risk
factors particular in the African population which is characterized
by marked genetic heterogeneity.
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